Nova Biomedical, Waltham, Mass, has received CLIA-waived status from the FDA for its StatStrip™ point of care blood glucose monitoring system.
The system can be used in point-of-care settings, screening clinics, and non-hospital locations that perform testing under a CLIA certificate of waiver.
The product measures and corrects hematocrit interference and interferences from acetaminophen (Tylenol), uric acid, ascorbic acid (Vitamin C), maltose, galactose, xylose, and lactose. It eliminates oxygen interference to provide glucose results regardless of the sample’s oxygen status.
NovaNet software provides management and control of point-of-care testing, and allows the system to be customized to the needs of testing locations.
